Pediatrix Medical Group Inc (MD) valuation
Pediatrix Medical Group P/E ratio history
Pediatrix Medical Group trades at 16.2 times its earnings over the last twelve months and 12.3 times the earnings analysts expect over the next twelve. At its last 6 fiscal year ends its P/E ranged from 11.0 (year to Dec 2025) to 19.1 (year to Dec 2016), with a median of 16.6.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $21.39 | $1.94 | 11.0 | 9.9 |
| Dec 31, 2024 | $13.12 | -$1.19 | n/m | 8.8 |
| Dec 31, 2023 | $9.30 | -$0.73 | n/m | — |
| Dec 31, 2022 | $14.86 | $0.79 | 18.8 | — |
| Dec 31, 2021 | $27.21 | $1.53 | 17.8 | 16.5 |
| Dec 31, 2020 | $24.54 | -$9.50 | n/m | — |
| Dec 31, 2019 | $27.79 | -$17.95 | n/m | — |
| Dec 31, 2018 | $33.00 | $2.93 | 11.3 | — |
| Dec 31, 2017 | $53.44 | $3.45 | 15.5 | — |
| Dec 31, 2016 | $66.66 | $3.50 | 19.1 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Pediatrix Medical Group valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Pediatrix Medical GroupMD | $2.42B | 16.2 | 12.3 | 1.2 |
| Supernus PharmaceuticalsSUPN | $2.43B | — | 10.9 | 2.9 |
| PrecigenPGEN | $2.47B | — | 16.6 | 28.9 |
| Brookdale Senior LivingBKD | $2.48B | — | — | 0.8 |
| Celldex TherapeuticsCLDX | $2.36B | — | — | — |
| Clover Health Investments Corp ClaCLOV | $2.35B | — | 30.8 | 1.0 |
| Addus HomecareADUS | $2.34B | 22.0 | 17.2 | 1.6 |
| Prestige Consumer HealthcarePBH | $2.32B | 13.7 | 10.4 | 2.1 |
| BiohavenBHVN | $2.32B | — | — | — |
| Peer median | 17.9 | 16.6 | 1.8 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: MD financials · MD returns
No forecast, no recommendation. This page describes Pediatrix Medical Group Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.